GSK announced £275 million of new investments at three of its manufacturing sites in the UK to boost production and support delivery of its latest innovative respiratory and large molecule biological medicines.
The vast majority of these products will be for export to global markets. GSK has a significant manufacturing presence in the UK, with nine sites employing approximately 6,000 people.
The investment announced today is split across three UK sites:
• Barnard Castle in County Durham is one of GSK’s biggest secondary manufacturing sites, employing 1,100 people. The site supplies nearly half a million packs of products per day to 140 global markets. The investment announced today of £92 million will fund the construction of an aseptic sterile facility supporting the manufacture of existing and new biopharmaceutical assets in our pipeline.
• Montrose in Angus in Scotland manufactures active ingredients for respiratory, HIV and vaccine products and employs over 450 staff. This investment of approximately £110 million will provide a new, state-of-the-art facility for the manufacture of respiratory active ingredients.
• Ware in Hertfordshire, employs 1200 staff, manufacturing innovative respiratory products. Today’s investment of £74 million will support further expansion of the company’s new Ellipta respiratory inhaler through additional manufacturing capacity at the site.
|Type||Boost Production And Support Delivery|
|Estimated Cost||£275 Million|
Source : gsk.com